Weigao Hemostasis: is currently advancing the acquisition of 100% equity of Weigao Pray by issuing shares.

Weigao Blood Purification released an announcement of abnormal fluctuations in stock trading. The closing prices of the company's stock on November 3 and November 4, 2025, exceeded a cumulative deviation of more than 20% over two consecutive trading days, indicating abnormal volatility in the stock trading. The company's current business operations are normal, with no significant fluctuations in recent costs and sales, and no major changes in the business environment, market environment, or industry policies. The company is currently progressing with a major asset restructuring transaction to acquire 100% equity of Weigao Pure by issuing new shares, which has been approved by the company's board of directors but still requires approval from the company's shareholders, with uncertainties remaining in related matters.